The not-so-terrible challenge for future trials of COVID-19 therapeutics

Several companies, including Pfizer, are developing antiviral drugs that could halt the progression of COVID-19 symptoms or prevent the onset of disease for close contacts of people with infections. Theoretically, the therapeutics would be another tool used to fight the coronavirus alongside vaccines.

Former Food and Drug Administration Commissioner Scott Gottlieb is confident there will be some successes, noting that the coronavirus isn't "a hard virus to drug in terms of how it replicates." But there is a bit of a race against the clock on this issue, although the reason for that probably won't be the worst thing you've heard since the pandemic began.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.